NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage antiviral drug developer, has highlighted the potential of its broad-spectrum antiviral candidate NV-387 in response to the ongoing Bundibugyo Ebola outbreak in the Democratic Republic of Congo and Uganda. The company stated that the oral drug candidate could offer a differentiated approach if proven effective against the virus strain.
The company emphasized NV-387’s proposed mechanism targeting viral cell attachment pathways common across filoviruses, positioning the candidate as a potential pandemic preparedness tool for Ebola and related viral threats. This comes as health authorities work to contain the outbreak, underscoring the need for effective treatments against emerging viral diseases.
NV-387 is NanoViricides’ lead drug candidate, a broad-spectrum antiviral drug that the company plans to develop as a treatment for respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as mpox/smallpox infections and even measles. The company is currently focused on advancing NV-387 into Phase II human clinical trials.
The company’s platform technology is based on the TheraCour nanomedicine technology, which NanoViricides holds a worldwide exclusive perpetual license for several drugs with specific targeting mechanisms for the treatment of various human viral diseases, including Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses.
NanoViricides’ drug candidate NV-CoV-2 (API NV-387) is designed for COVID-19 and does not encapsulate remdesivir, while NV-CoV-2-R encapsulates remdesivir within its polymeric micelles. The company believes that since remdesivir is already US FDA approved, their drug candidate encapsulating remdesivir is likely to be approvable if safety is comparable. Remdesivir is developed by Gilead.
The announcement of NV-387’s potential against Ebola highlights the broader implications for pandemic preparedness. As the world faces emerging viral threats, broad-spectrum antivirals that can target multiple viruses are critical. If NV-387 proves effective against the Bundibugyo Ebola strain, it could provide an oral treatment option that is easier to administer in outbreak settings compared to injectable therapies. This could significantly impact outbreak response, especially in resource-limited regions.
However, the company cautions that the path to typical drug development is extremely lengthy and requires substantial capital. There can be no assurance that any of the company’s pharmaceutical candidates will show sufficient effectiveness and safety for human clinical development. “As with any drug development efforts by any company, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product,” the company stated.
For more information, visit the company’s newsroom at https://ibn.fm/NNVC and the full press release at https://ibn.fm/mm3Z5.
